Compare Stocks: BHVN, ALKS, IMVT, and KNSA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$39.73 -1.3%	$45.55	$27.00 ▼ $55.67	$6.75B	0.32	2.63 million shs	1.07 million shs
BHVN Biohaven	$11.46 -3.0%	$13.89	$7.48 ▼ $18.57	$1.78B	1.35	2.57 million shs	2.43 million shs
IMVT Immunovant	$28.71 -2.6%	$38.02	$16.77 ▼ $45.42	$6.09B	0.84	1.69 million shs	1.24 million shs
KNSA Kiniksa Pharmaceuticals International	$78.53 -0.9%	$77.74	$35.20 ▼ $82.94	$6.18B	0.04	531,255 shs	575,784 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.86%	-5.85%	-12.42%	-21.98%	+29.00%
BHVN Biohaven	-2.81%	-9.64%	-7.77%	-21.46%	-25.96%
IMVT Immunovant	-3.25%	-11.34%	-21.09%	-23.96%	+73.11%
KNSA Kiniksa Pharmaceuticals International	-0.68%	+3.84%	+3.89%	+27.85%	+109.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$39.73 -1.3%	$45.55	$27.00 ▼ $55.67	$6.75B	0.32	2.63 million shs	1.07 million shs
BHVN Biohaven	$11.46 -3.0%	$13.89	$7.48 ▼ $18.57	$1.78B	1.35	2.57 million shs	2.43 million shs
IMVT Immunovant	$28.71 -2.6%	$38.02	$16.77 ▼ $45.42	$6.09B	0.84	1.69 million shs	1.24 million shs
KNSA Kiniksa Pharmaceuticals International	$78.53 -0.9%	$77.74	$35.20 ▼ $82.94	$6.18B	0.04	531,255 shs	575,784 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.86%	-5.85%	-12.42%	-21.98%	+29.00%
BHVN Biohaven	-2.81%	-9.64%	-7.77%	-21.46%	-25.96%
IMVT Immunovant	-3.25%	-11.34%	-21.09%	-23.96%	+73.11%
KNSA Kiniksa Pharmaceuticals International	-0.68%	+3.84%	+3.89%	+27.85%	+109.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.74	Moderate Buy	$54.47	37.10% Upside
BHVN Biohaven	2.59	Moderate Buy	$18.69	63.14% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	53.26% Upside
KNSA Kiniksa Pharmaceuticals International	2.89	Moderate Buy	$93.14	18.61% Upside

Current Analyst Ratings Breakdown

Latest BHVN, ALKS, IMVT, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy
10/2/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$87.00
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Positive
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$50.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold	$50.00
9/23/2026	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/22/2026	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$56.00
9/22/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$58.00 ➝ $61.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	4.52	$1.65 per share	24.05	$11.02 per share	3.61
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$677.56M	9.04	$0.79 per share	99.83	$7.44 per share	10.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	93.63	165.54	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	80.96	37.94	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)

Latest BHVN, ALKS, IMVT, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	BHVN Biohaven	-$0.6097	N/A	N/A	N/A	$70.00 million	N/A
11/9/2026	Q2 2027	IMVT Immunovant	-$0.73	N/A	N/A	N/A	$7.10 million	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0788	N/A	N/A	N/A	$463.35 million	N/A
10/27/2026	Q3 2026	KNSA Kiniksa Pharmaceuticals International	$0.3699	N/A	N/A	N/A	$259.65 million	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
BHVN Biohaven	21.23	4.73	4.73
IMVT Immunovant	N/A	7.27	7.27
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
BHVN Biohaven	88.78%
IMVT Immunovant	47.08%
KNSA Kiniksa Pharmaceuticals International	53.95%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
BHVN Biohaven	13.80%
IMVT Immunovant	1.90%
KNSA Kiniksa Pharmaceuticals International	51.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
BHVN Biohaven	274	151.04 million	130.20 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable

BHVN, ALKS, IMVT, and KNSA Headlines

Recent News About These Companies

Kiniksa Pharmaceuticals International, plc (KNSA)

October 9, 2026 | finance.yahoo.com

Kiniksa Pharmaceuticals Has Strong Growth And Little Room For Disappointment

October 2, 2026 | seekingalpha.com

Wells Fargo & Company Begins Coverage on Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

October 2, 2026 | americanbankingnews.com

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Coverage Initiated by Analysts at Wells Fargo & Company

September 30, 2026 | marketbeat.com

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Consensus Price Target of $87.38 According to Brokerages

September 25, 2026 | marketbeat.com

Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued

September 23, 2026 | finance.yahoo.com

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

September 17, 2026 | zacks.com

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

September 11, 2026 | investors.com

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

September 4, 2026 | globenewswire.com

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

August 7, 2026 | globenewswire.com

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

August 3, 2026 | zacks.com

G Bradley Cole Sells 3,673 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

August 1, 2026 | insidertrades.com

Kiniksa Pharmaceuticals International, plc 2026 Q2 - Results - Earnings Call Presentation

July 31, 2026 | seekingalpha.com

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

July 30, 2026 | zacks.com

Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?

July 29, 2026 | finance.yahoo.com

Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline

July 29, 2026 | finance.yahoo.com

Kiniksa Pharmaceuticals Announces Q2 2026 Financial Results on July 28, 2026

July 29, 2026 | kalkinemedia.comK

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates

July 28, 2026 | zacks.com

Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.30 beats by $0.01, revenue of $243.6M beats by $17.14M

July 28, 2026 | seekingalpha.com

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

July 28, 2026 | globenewswire.com

Kiniksa Pharmaceuticals International, plc Q2 2026 earnings preview

July 27, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BHVN, ALKS, IMVT, and KNSA Company Descriptions

Alkermes NASDAQ:ALKS

$39.73 -0.53 (-1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$39.72 0.00 (-0.01%)

As of 07:30 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Biohaven NYSE:BHVN

$11.46 -0.36 (-3.01%)

Closing price 03:59 PM Eastern

Extended Trading

$11.50 +0.05 (+0.40%)

As of 08:00 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Immunovant NASDAQ:IMVT

$28.71 -0.77 (-2.61%)

Closing price 04:00 PM Eastern

Extended Trading

$28.54 -0.18 (-0.61%)

As of 07:30 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$78.53 -0.71 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$78.58 +0.05 (+0.06%)

As of 07:30 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHVN, ALKS, IMVT, and KNSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHVN, ALKS, IMVT, and KNSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHVN, ALKS, IMVT, and KNSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BHVN, ALKS, IMVT, and KNSA Company Descriptions

Alkermes NASDAQ:ALKS

Biohaven NYSE:BHVN

Immunovant NASDAQ:IMVT

Kiniksa Pharmaceuticals International NASDAQ:KNSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHVN, ALKS, IMVT, and KNSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHVN, ALKS, IMVT, and KNSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHVN, ALKS, IMVT, and KNSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BHVN, ALKS, IMVT, and KNSA Company Descriptions

Alkermes NASDAQ:ALKS

Biohaven NYSE:BHVN

Immunovant NASDAQ:IMVT

Kiniksa Pharmaceuticals International NASDAQ:KNSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools